Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Radius Health (RDUS)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,277,949
  • Shares Outstanding, K 44,590
  • Annual Sales, $ 0 K
  • Annual Income, $ -182,800 K
  • 36-Month Beta 1.09
  • Price/Sales 88.44
  • Price/Cash Flow N/A
  • Price/Book 4.21

Price Performance

See More
Period Period Low Period High Performance
1-Month
25.80 +16.20%
on 12/07/17
32.33 -7.27%
on 12/08/17
+3.15 (+11.74%)
since 11/15/17
3-Month
24.66 +21.57%
on 11/14/17
40.79 -26.50%
on 10/03/17
-3.56 (-10.61%)
since 09/15/17
52-Week
24.66 +21.57%
on 11/14/17
49.16 -39.02%
on 07/12/17
-13.95 (-31.76%)
since 12/15/16

Most Recent Stories

More News
Radius Health Announces that the Committee for Medicinal Products for Human Use (CHMP) Will Issue a Third Day-180 List of Outstanding Issues in its Regulatory Review of Abaloparatide-SC, a Bone Building Agent for the Treatment of Osteoporosis in Postmenopausal Women at Increased Risk of Fracture

Radius Health, Inc. (Nasdaq:RDUS) announced today that the Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the European Medicines Agency (EMA), will issue a third Day-180...

RDUS : 29.98 (+4.61%)
Fractured Truth Campaign Wins Bronze Pearl Award for Content Marketing Excellence in the Healthcare/Pharmaceutical Industry

Radius Health, Inc. (Nasdaq:RDUS) today announced that Fractured Truth--an unbranded patient campaign aimed to educate younger postmenopausal women about risks associated with osteoporosis--won the Bronze...

RDUS : 29.98 (+4.61%)
Radius Investigational Drug Elacestrant (RAD1901) Continues to Show Promise in Advanced ER+ / HER2- Breast Cancer at the 2017 San Antonio Breast Cancer Symposium

-Elacestrant 400mg single agent Objective Response Rate (ORR) was 27.3% in heavily pre-treated patients with advanced ER+ breast cancer at the pre-determined study cutoff date of October 30, 2017-

RDUS : 29.98 (+4.61%)
New Research: Key Drivers of Growth for First Data, Target, Kellogg, Builders FirstSource, HD Supply, and Radius Health -- Factors of Influence, Major Initiatives and Sustained Production

In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of First Data Corporation (NYSE:FDC),...

TGT : 62.61 (+1.08%)
FDC : 16.48 (+1.35%)
HDS : 38.39 (+1.45%)
RDUS : 29.98 (+4.61%)
BLDR : 20.05 (+1.62%)
K : 64.99 (-0.09%)
Radius Health Announces Commercial Leadership Changes with Appointment of Joseph Kelly as Senior Vice President of Sales and Marketing, and Promotion of Amanda Mott to Senior Vice President of Market Access

Radius Health, Inc. ("Radius" or the "Company") (Nasdaq:RDUS) today announced the appointment of Joseph Kelly as Senior Vice President of Sales and Marketing, and the promotion of Amanda Mott to Senior...

RDUS : 29.98 (+4.61%)
Corporate News Blog - OncoSec Medical Reports Positive Updated Follow-Up Data from Phase-2 Trial of ImmunoPulse IL-12 in Combination with Pembrolizumab

Research Desk Line-up: Radius Health Post Earnings Coverage

RDUS : 29.98 (+4.61%)
ONCS : 1.59 (-7.02%)
Radius Health (RDUS) Earnings Miss in Q3, Tymlos in Focus

Radius Health (RDUS) reported a wider-than-expected loss in third-quarter as expenses grew significantly for the commercialization of Tymlos.

RDUS : 29.98 (+4.61%)
LLY : 86.54 (+0.05%)
EXEL : 26.10 (+0.58%)
AMGN : 177.04 (+1.21%)
Radius Health Reports Third Quarter 2017 Financial and Operating Results and Provides Business Update

First full quarter of TYMLOS(TM) sales shows accelerating market share & stabilization of the anabolic market

RDUS : 29.98 (+4.61%)
Radius Health Inc to Host Earnings Call

NEW YORK, NY / ACCESSWIRE / November 2, 2017 / Radius Health Inc (NASDAQ: RDUS) will be discussing their earnings results in their Q3 Earnings Call to be held on November 2, 2017 at 4:30 PM Eastern Time....

RDUS : 29.98 (+4.61%)
Will Radius Health (RDUS) Disappoint This Earnings Season?

Radius Health (RDUS) has a disappointing track record and we expect the trend to continue when it reports third-quarter results on Nov 2.

RDUS : 29.98 (+4.61%)
LLY : 86.54 (+0.05%)
INCY : 96.41 (+0.46%)
AMGN : 177.04 (+1.21%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 16% Sell with a Weakest short term outlook on maintaining the current direction.

Longer term, the trend strength is Weak. Long term indicators fully support a continuation of the trend.

See More

Business Summary

Radius Health Inc. is a science-driven biopharmaceutical company. It is focused on developing novel differentiated therapeutics for patients with osteoporosis as well as other serious endocrine-mediated diseases. The Company's lead product candidate, abaloparatide (BA058), is in development, in both...

See More

Key Turning Points

2nd Resistance Point 32.41
1st Resistance Point 31.19
Last Price 29.98
1st Support Level 27.99
2nd Support Level 26.01

See More

52-Week High 49.16
Fibonacci 61.8% 39.80
Fibonacci 50% 36.91
Fibonacci 38.2% 34.02
Last Price 29.98
52-Week Low 24.66

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
New Chart Menu
Right-click anywhere on the chart to open the Interactive Chart menu.